• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Omeros Corporation filed SEC Form 8-K: Other Events

    6/18/26 7:52:18 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OMER alert in real time by email
    omer20260618_8k.htm
    false 0001285819 0001285819 2026-06-17 2026-06-17
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

    FORM 8-K
     

    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 17, 2026
     

    OMEROS CORPORATION
    (Exact name of Registrant as Specified in Its Charter)
     

     
    Washington
    001-34475
    91-1663741
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
     
     
     
    201 Elliott Avenue West
    Seattle, WA
     
    98119
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s Telephone Number, Including Area Code: (206) 676-5000
     
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities Registered Pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common stock, par value $0.01 per share
    OMER
    The Nasdaq Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     

     
    Item 8.01 Other Events.
     
    On June 17, 2026, Omeros Corporation (the “Company”) entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the “Notes”) under which it agreed to repurchase Notes having an aggregate principal amount of up to approximately $16.0 million for a total purchase price, inclusive of accrued and unpaid interest and all other obligations, of up to approximately $34.0 million, subject in each case to adjustment based on the trading price of the Company’s common stock during an averaging period beginning on June 18, 2026, and customary closing conditions. The Company expects the repurchases to close between July 6, 2026 and July 16, 2026, following the completion of the averaging period. If the full $16.0 million aggregate principal amount of Notes is repurchased, approximately $54.8 million aggregate principal amount of Notes will remain outstanding following the repurchases.
     

     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
     
     
     
    OMEROS CORPORATION
     
     
     
    Date: June 18, 2026
    By:
    /s/ Gregory A. Demopulos
     
     
    Gregory A. Demopulos, M.D.
     
     
    President, Chief Executive Officer and
     
     
    Chairman of the Board of Directors
     
    Get the next $OMER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMER

    DatePrice TargetRatingAnalyst
    6/10/2025$9.00Buy
    H.C. Wainwright
    12/23/2024$36.00Buy
    D. Boral Capital
    11/14/2024$9.00Buy
    Rodman & Renshaw
    12/8/2022$12.00 → $2.00Buy → Neutral
    UBS
    11/8/2022$8.00 → $3.00Neutral → Underperform
    BofA Securities
    6/8/2022$12.00 → $4.00Buy → Neutral
    BofA Securities
    10/19/2021$19.00 → $12.00Buy
    HC Wainwright & Co.
    10/8/2021Neutral → Underweight
    JP Morgan
    More analyst ratings

    $OMER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Shah Rajiv

    4 - OMEROS CORP (0001285819) (Issuer)

    6/22/26 7:35:28 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Perkinson Diana T.

    4 - OMEROS CORP (0001285819) (Issuer)

    6/22/26 7:34:52 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hood Leroy E. Md Phd

    4 - OMEROS CORP (0001285819) (Issuer)

    6/22/26 7:34:16 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Omeros with a new price target

    H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    6/10/25 8:09:22 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Omeros with a new price target

    D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00

    12/23/24 7:27:28 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Omeros with a new price target

    Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    11/14/24 7:47:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/21/23 8:11:35 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/17/23 9:46:20 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omeros Announces Webcast Details for Annual Meeting of Shareholders

    Omeros Corporation (NASDAQ:OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 18, 2026, beginning at 10:00 a.m. Pacific Time. The live webcast can be accessed through the virtual shareholder meeting website at www.virtualshareholdermeeting.com/OMER2026. A general corporate overview and question-and-answer session will follow the business portion of the annual meeting. As described in the company's proxy statement, filed April 30, 2026, only shareholders of record as of the close of business on April 17, 2026 are entitled to vote at the Annual Meeting of Shareholders and any adjournment or

    6/15/26 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation Reports First Quarter 2026 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or $0.58 per share, for the first quarter of 2025. First quarter results include a $73

    5/13/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Investor Relations page of Omeros'

    5/11/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    SEC Filings

    View All

    Omeros Corporation filed SEC Form 8-K: Other Events

    8-K - OMEROS CORP (0001285819) (Filer)

    6/18/26 7:52:18 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Omeros Corporation

    10-Q - OMEROS CORP (0001285819) (Filer)

    5/13/26 4:07:55 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OMEROS CORP (0001285819) (Filer)

    5/13/26 4:06:59 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Financials

    Live finance-specific insights

    View All

    Omeros Corporation Reports First Quarter 2026 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or $0.58 per share, for the first quarter of 2025. First quarter results include a $73

    5/13/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Investor Relations page of Omeros'

    5/11/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth

    3/31/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Leadership Updates

    Live Leadership Updates

    View All

    Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

    SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development

    4/20/26 7:00:00 AM ET
    $OMER
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

    Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch

    10/19/23 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/24 2:47:02 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    2/14/24 6:05:17 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Omeros Corporation

    SC 13G - OMEROS CORP (0001285819) (Subject)

    2/13/24 5:12:07 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care